DIPG-27. OPTIMIZING CLINICAL TRIAL DESIGN: PHARMACOKINETICS OF MARIZOMIB AND PANOBINOSTAT IN A NON-HUMAN PRIMATE MODEL

BACKGROUND: Pre-clinical determination of disease-specific activity, effective dosing, safety, pharmacokinetics, and CNS delivery can optimize clinical trial designs. The proteasome inhibitor, marizomib, together with the HDAC inhibitor, panobinostat, is active and synergistic in pre-clinical DIPG s...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Neuro Oncol
Prif Awduron: Warren, Katherine, Shankarappa, Priya, Peer, Cody, Garcia, Rafael Cruz, Monje-Deisseroth, Michelle, Figg, W Doug, McCully, Cynthia Lester
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2019
Pynciau:
Diffuse Intrinsic Pontine Glioma (DIPG)
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477305/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz036.048
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg